COPD急性加重期的炎性指标临床研究

Clinical research on inflammatory indicators of AECOPD

目的研究慢性阻塞性肺疾病急性发作期患者血清C反应蛋白(CRP)、趋化因子配体18(CCL18)含量变化及临床意义。方法检测30例COPD急性加重期、第7天和缓解期及30例体检者血清CRP、CCL18浓度,同时测定1 s用力呼气容积占预计值百分数(FEV1%pred)和动脉血氧分压(PaO2)。结果COPD急性加重期患者及缓解期血清CRP和CCL18水平较对照组均明显升高,有显著差异性(P<0.05);而治疗组缓解期血清CRP和CCL18水平均较急性发作期明显降低,具有统计学意义(P<0.01)。COPD患者CRP和CCL18水平与FEV1%pred、PaO2均呈直线负相关关系(P<0.05)。结论检测血清CRP和CCL18对COPD发生发展及疾病严重程度的判断,指导抗生素的使用有一定意义。

Objective To study the changes of serum C-reactive protein （CRP） and chemokine CC-motif ligand 18 （CCL18） in patients with AECOPD. Methods The levels of serum CRP and CCL18 were detected in 30 AECOPD patients and 30 healthy people respectively. At the same time, the percentage of FEV1%pred and arterial blood oxygen partial pressure （PaO2） were detected. Results The levels of CRP and CCL18 were higher in the observation group than in the control group （F=162.23, 81.54; P〈0.01, 0.03）. After the treatment, the levels of CRP and CCL18 decreased obviously. The levels of CRP and CCL18 were negatively correlated with FEV1% （r=-0.781~0.693, P〈0.05）. Conclusion The determination of serum CRP and CCL18 has certain significance in the assessment of status and therapy of AECOPD, which can guide the use of antibiotics.